Acadian Asset Management LLC Increases Stock Position in Pfizer Inc. $PFE

Acadian Asset Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 676,698 shares of the biopharmaceutical company’s stock after buying an additional 70,847 shares during the quarter. Acadian Asset Management LLC’s holdings in Pfizer were worth $17,141,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Geneos Wealth Management Inc. boosted its stake in Pfizer by 8.5% during the first quarter. Geneos Wealth Management Inc. now owns 59,158 shares of the biopharmaceutical company’s stock worth $1,499,000 after buying an additional 4,614 shares during the period. Bluefin Capital Management LLC purchased a new position in Pfizer during the first quarter worth about $441,000. Acorns Advisers LLC boosted its stake in Pfizer by 10.5% during the first quarter. Acorns Advisers LLC now owns 9,416 shares of the biopharmaceutical company’s stock worth $239,000 after buying an additional 893 shares during the period. Blue Rock Wealth Management LLC purchased a new position in Pfizer during the first quarter worth about $325,000. Finally, Focus Partners Wealth boosted its stake in Pfizer by 14.5% during the first quarter. Focus Partners Wealth now owns 1,502,189 shares of the biopharmaceutical company’s stock worth $38,066,000 after buying an additional 190,288 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PFE shares. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Jefferies Financial Group upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. Berenberg Bank cut their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Finally, HSBC cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Stock Up 1.1%

Shares of NYSE:PFE opened at $24.84 on Friday. The firm’s 50 day moving average price is $24.82 and its 200 day moving average price is $24.32. The stock has a market cap of $141.23 billion, a price-to-earnings ratio of 13.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.